Outcome after relapse of myelodysplastic syndrome and secondary

  • Slides: 10
Download presentation
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation by Christoph Schmid, Liesbeth C. de Wreede, Anja van Biezen, Jürgen Finke, Gerhard Ehninger, Arnold Ganser, Liisa Volin, Dietger Niederwieser, Dietrich Beelen, Paolo Alessandrino, Lothar Kanz, Michael Schleuning, Jakob Passweg, Hendrik Veelken, Johan Maertens, Jan J. Cornelissen, Didier Blaise, Martin Gramatzki, Noel Milpied, Ibrahim Yakoub-Agha, Ghulam Mufti, Montserrat Rovira, Renate Arnold, Theo de Witte, Marie Robin, and Nikolaus Kröger haematol Volume 103(2): 237 -245 January 31, 2018 © 2018 by Ferrata Storti Foundation

Baseline characteristics of 698 patients relapsing after allogeneic stem cell transplantation for myelodysplastic syndrome

Baseline characteristics of 698 patients relapsing after allogeneic stem cell transplantation for myelodysplastic syndrome or secondary acute myeloid leukemia. Christoph Schmid et al. Haematologica 2018; 103: 237 -245 © 2018 by Ferrata Storti Foundation

Overall survival from relapse in 698 patients. Christoph Schmid et al. Haematologica 2018; 103:

Overall survival from relapse in 698 patients. Christoph Schmid et al. Haematologica 2018; 103: 237 -245 © 2018 by Ferrata Storti Foundation

Multivariate analysis of risk factors for overall survival from relapse in 698 patients. Christoph

Multivariate analysis of risk factors for overall survival from relapse in 698 patients. Christoph Schmid et al. Haematologica 2018; 103: 237 -245 © 2018 by Ferrata Storti Foundation

Cumulative incidence of treatments applied during the first 6 months. Christoph Schmid et al.

Cumulative incidence of treatments applied during the first 6 months. Christoph Schmid et al. Haematologica 2018; 103: 237 -245 © 2018 by Ferrata Storti Foundation

Characteristics and early outcome of second transplant in 110 patients. Christoph Schmid et al.

Characteristics and early outcome of second transplant in 110 patients. Christoph Schmid et al. Haematologica 2018; 103: 237 -245 © 2018 by Ferrata Storti Foundation

Overall survival after second transplant. Christoph Schmid et al. Haematologica 2018; 103: 237 -245

Overall survival after second transplant. Christoph Schmid et al. Haematologica 2018; 103: 237 -245 © 2018 by Ferrata Storti Foundation

Multivariate analysis of risk factors for overall survival from second transplant in 110 patients.

Multivariate analysis of risk factors for overall survival from second transplant in 110 patients. Christoph Schmid et al. Haematologica 2018; 103: 237 -245 © 2018 by Ferrata Storti Foundation

Overall survival after first therapeutic donor lymphocyte infusion. Christoph Schmid et al. Haematologica 2018;

Overall survival after first therapeutic donor lymphocyte infusion. Christoph Schmid et al. Haematologica 2018; 103: 237 -245 © 2018 by Ferrata Storti Foundation

Multivariate analysis of risk factors for overall survival after first therapeutic donor lymphocyte infusion

Multivariate analysis of risk factors for overall survival after first therapeutic donor lymphocyte infusion in 213 patients. Christoph Schmid et al. Haematologica 2018; 103: 237 -245 © 2018 by Ferrata Storti Foundation

Outcome after relapse of myelodysplastic syndrome and secondaryOutcome after relapse of myelodysplastic syndrome and secondary
Myelodysplastic syndromes Achievements in understanding and treatment MyelodysplasticMyelodysplastic syndromes Achievements in understanding and treatment Myelodysplastic
Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized byMyelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by
Relapse Renaissance and Reformation 9 1 Relapse TheRelapse Renaissance and Reformation 9 1 Relapse The
Relapse Renaissance and Reformation 9 1 Relapse TheRelapse Renaissance and Reformation 9 1 Relapse The
Relapse or Relapse Prevention A Choice CAPTASA 2016Relapse or Relapse Prevention A Choice CAPTASA 2016
Integrated Relapse Prevention Is avoiding relapse twice asIntegrated Relapse Prevention Is avoiding relapse twice as
Myelodysplastic Syndrome MDS and Myelofibrosis Syndromes Whats NextMyelodysplastic Syndrome MDS and Myelofibrosis Syndromes Whats Next
Myelodysplastic Syndrome MDS email wuyuscu edu cn 18980601973Myelodysplastic Syndrome MDS email wuyuscu edu cn 18980601973